Category Archives: Regenerative Medicine

Stan Wang talks about creating non-embryonic stem for use n regenerative medicine
Gates Cambridge Scholar Stan Wang is pursuing a PhD in medicine supervised by recent Nobel Prize winner Sir John Gurdon. Stan works on a technique which takes tissue from any part the human body and gives it embryonic stem cell-like properties. This could have a huge impact on the world of regenerative medicine.

By: GatesCambridge

Read the rest here:
Stan Wang talks about creating non-embryonic stem for use n regenerative medicine - Video

As we discussed in our first article on elite regenerative medicine companies, there are several methodologies to delineating the cream of the crop. In this exercise, we will take a look at the impact that regenerative medicine technologies can have on ischemic conditions where tissue in the heart, brain, organs or limbs are damaged as a result of restricted blood flow and identify some of the most innovative companies that have a strong upside based on the products and technologies they are developing, stage of development, and current valuations.

Ischemic conditions are expansive, covering common conditions such as stroke, heart disease and peripheral vascular disease (which in severe cases can result in critical limb ischemia, requiring amputation of digits or limbs). The economic impact of these types of conditions is also substantial. Research by the American Heart Association indicates that cardiovascular disease (most of which is ischemic in nature) comprises more than $300 billion in healthcare related expenses annually, accounting for more than 17% of total healthcare related expenses in the U.S. Furthermore, these conditions impose a huge quality of life burden for patients and their families, and therefore are areas of great unmet medical need.

From a company and investor perspective, they represent multi-billion-dollar opportunities. Cumulatively, hundreds of millions of people are affected globally, but traditional medicines and clinical treatments provide little benefit. Regenerative medicine technologies represent new options that could yield a new age of therapies and viable solutions for patients that presently have very few, if any, options.

In our initial article, Cytomedix, Inc. (OTCQX:CMXI) was omitted from the top five because of the broad scope of credentials defining companies with obvious headroom for growth. Within the parameters of ischemia-related treatments, however, the Gaithersburg, Maryland-based developer of biologically active regenerative therapies deserves a strong mention.

Cytomedix is developing platelet technologies for orthopedics and wound care and a pipeline of autologous (patient-derived) stem cell therapies for tissue repair. The company is already generating revenue through its AutoloGel System, a platelet rich plasma (PRP) producing device for exuding wounds, and its Angel Whole Blood Separation System, a blood processing device for separating whole blood into red cells, platelet poor plasma (PPP) and PRP for use in surgical and orthopedic settings. For the third quarter of 2012, total revenues increased 15% to $1.76 million from $1.53 million in the year prior quarter.

Honing in on the ischemic conditions, through the acquisition of Aldagen in February at a bargain price of $16 million in stock (plus additional shares upon milestones being met), Cytomedix gained control of Aldagens proprietary ALDH bright cell (ALDHbr) technology and finally made the transition from just a wound care company to cement its position as a leading developer of a promising new therapy to treat patients that have recently suffered a stroke.

The ALDHbr technology is used to isolate biologically active stem cells which have previously shown the potential to promote cell and tissue regeneration in preclinical studies. The cells are isolated from the patients own bone marrow, shipped to the company for subsequent expansion, and are then reinfused into the patient roughly 3 weeks later. A 100-patient Phase 2 trial for the treatment of ischemic stroke using ALDHbr Bright Cells derived from a patients own bone marrow is underway that will involve patients from 12 to 15 sites in the United States. Safety data from the first 10 patients in the Phase II RECOVER-Stroke study of ALD-401 were recently presented at the World Stroke Congress in Brazil showing a solid safety profile.

The clinical trials aim to build upon promising laboratory research. Mice treated with ALD-401 two weeks after an induced stroke demonstrated nearly four-fold improvement in motor function compared to controls. Further, stark improvements were seen in ALD-401 slowing decreases in brain volume and the reversal of decline in stroke-induced cell viability. Additional studies with ALD-401 in animal models showed perfusion (blood flow) levels returning to normal after four weeks in stroke-induced subjects receiving the ALDHbr cell treatment while untreated controls remained impaired.

This study is only one of several clinical trials being conducted to test Cytomedixs ALDHbr technology. ALD-201 has completed a Phase I clinical trial testing its safety as a therapeutic candidate for ischemic heart failure. The 20-patient trial showed ALD-201 to be well-tolerated and produced a statistically significant reduction in ischemia as well as improvement in MaxVO2, a measure of the bodys ability to take up oxygen during exercise, in patients receiving the ALDHbr therapy as compared to a placebo group.

In a 21-patient Phase 1/2 clinical trial on ALD-301 testing critical limb ischemia with no revascularization options, the treatment was again well-tolerated with data indicating improved blood flow. Patients with this condition face a 35% risk of limb amputation, but 10 of the 11 patients (91%) treated with ALD-301 required no such procedure.

Original post:
Top Three Regenerative Medicine Companies Targeting Ischemic Conditions

10 Reasons to attend the World Stem Cell Regenerative Medicine Congress
Why should you attend? Watch the video to find out.

By: biopharmachannel

Read more here:
10 Reasons to attend the World Stem Cell

Public release date: 9-Jan-2013 [ | E-mail | Share ]

Contact: Antonio Campos Muoz acampos@ugr.es 34-958-243-514 University of Granada

Scientists at the University of Granada and Alcal de Henares University have found out that not all isolated stem cells are equally valid in regenerative medicine and tissue engineering. In a paper recently published in the prestigious journal Tissue Engineering the researchers report that, contrary to what was thought, only a specific group of cord blood stem cells (CB-SC) maintained in culture are useful for therapeutic purposes.

At present, CB-SCs are key to regenerative medicine and tissue engineering. From all types of CB-SC those called "Wharton's jelly stem cells (HWJSC)" are stirring up the interest of specialists in regenerative medicine, due to their accessibility and great ability to develop into several types of tissue and modulate immune responses.

Through a combination of microscopy and microanalysis essays, and the study of the genes involved in cell viability, the researchers discovered that only a specific group of cord blood stem cells (CB-SC) maintained in culture is useful for therapeutic purposes

The Most Suitable Cells

The relevance of this paper, which was the cover article in the journal Tissue Engineering, lies in the possibility to select the most suitable HWJSC for tissue engineering and regenerative medicine. According to these researchers, the different studies with HWJSC have obtained contradictory results because researchers failed to previously select the most suitable cell group.

The results of this study also open the possibility to select stem cell subgroups from different tissues, in order to improve the therapeutical efficacy of different regenerative medicine protocols.

###

This research study was conducted by the Tissue Engineering research group at the University of Granada Histology Department coordinated by professor Antonio Campos Muoz, who recently created artificial skin and a cornea by using stem cells and new biomaterials developed in Granada.

Read the rest here:
Not all stem cells are equally efficient for use in regenerative medicine

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/ABphTtPOrwo/cell-therapy-blog-welcomes-2013.html

The best pain clinic in Scottsdale, Arizona Pain Specialists, is now offering regenerative medicine injections with platelet rich plasma therapy. The PRP injections represent cutting edge technology in pain management and are showing excellent results for tendon and ligament injuries along with arthritis pain.

Scottsdale, AZ (PRWEB) December 31, 2012

Arizona Pain Specialists continually offers ground breaking technology to patients that is effective and safe. Platelet Rich Plasma is a technology that utilizes a patient's own blood. The blood is spun down using a centrifuge into plasma containing platelets and growth factors. The resulting solution, PRP, is reinjected into the patient's problem area, which helps repair the damage.

There have been numerous studies performed on PRP therapy, and according to the American Academy of Orthopedic Surgeons three professional sports leagues now approve of the use of platelet rich plasma treatment. The therapy is being used to treat tendon injury such as rotator cuff tendonitis, achilles tendonitis, knee, hip and elbow injury.

Along with tendon damage, ligament injuries are also being helped with PRP. This includes the collateral ligaments of the knee and more. Recently, the use of PRP has extended to arthritic conditions as well.

"Platelet rich plasma is great because the risks are low and the treatment calls in the body's own stem cells. So they turn into a form of stem cell injection therapy, and results in initial studies are showing extremely promising results," said David Greene, CEO of the Arizona Pain Network.

Along with providing pain management Scottsdale trusts, Arizona Pain also has clinics in Glendale and Chandler. This makes it convenient to serve those in Phoenix, Mesa, Gilbert, Tempe, Surprise, Goodyear and surrounding areas.

For more information regarding this amazing new technology, call (480) 535-7370.

Jennifer Arizona Pain Specialists (480) 535-7370 Email Information

Go here to see the original:
Best Scottsdale Pain Management Clinic Now Offering Regenerative Medicine With Platelet Rich Plasma Injections

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/ABphTtPOrwo/cell-therapy-blog-welcomes-2013.html

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/z30UCNTkzIQ/the-accuracy-of-adipose-stem-cell-doses.html

Source:
http://feedproxy.google.com/~r/CellTherapyBlog/~3/z30UCNTkzIQ/the-accuracy-of-adipose-stem-cell-doses.html

Arizona Pain Specialists, the leading pain clinics in Phoenix and Scottsdale metropolitan areas, are now offering cutting edge platelet rich plasma injections. Also known as PRP for short, the regenerative medicine injections work well for relieving pain by recruiting the body's stem cells to repair the damaged area.

Phoenix, AZ (PRWEB) December 19, 2012

Regenerative medicine with PRP represents the current state of the art treatment in pain management. Most treatments up until recently have been good at pain relief by masking the problem, rather than repairing it. While these treatments, such as cortisone injections, are excellent at short term pain relief, they are not fixing the actual problem.

Platelet rich plasma actually provides growth factors which have the potential to regenerate damaged cartilage, tendons and ligament. The treatment consists of using the patient's own blood from a simple blood draw, and centrifuging the specimen to obtain the platelets and growth factors in the plasma.

The PRP injection has shown significant benefit in initial studies, including a review by Sampson et al from a 2008 Current Review Musculoskeletal Medicine study. The injections are beneficial for tendinitis of the elbow, shoulder, hip, knee and ankle. Reviews are also showing benefit for arthritis as well.

Regenerative medicine with PRP represents the cutting edge in modern medicine for musculoskeletal conditions. It represents a different approach to treating painful conditions, and Arizona Pain takes pride in offering the latest therapies while taking care to preserve patient safety.

The Board Certified and Fellowship Trained doctors at Arizona Pain Specialists offer platelet rich plasma injections as an outpatient treatment. Phoenix pain management services are available across the valley serving Glendale, Scottsdale, Chandler, Mesa, Surprise, Tempe, Goodyear and more.

More information and scheduling is available at (602) 507-6550.

Jennifer Arizona Pain Specialists (602) 507-6550 Email Information

Original post:
Best Pain Clinics in AZ, Arizona Pain Specialists, Now Offering Regenerative Medicine with Platelet Rich Plasma ...